MD Anderson and Replay announce FDA clearance of IND application for first-in-class PRAME-targeted TCR NK cell therapy for hematological malignancies
HOUSTON, SAN DIEGO and LONDON ― The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA)...
